A citation-based method for searching scientific literature

Jeff P Sharman, Andres Forero-Torres, Luciano J Costa, Ian W Flinn, Lowell Inhorn, Kevin Kelly, Alberto Bessudo, Luis E Fayad, Mark S Kaminski, Andrew M Evens, Christopher R Flowers, Deniz Sahin, Kirsten E Mundt, Thomas Sandmann, Günter Fingerle-Rowson, Charlotte Vignal, Mehrdad Mobasher, Andrew D Zelenetz. Leuk Lymphoma 2019
Times Cited: 12







List of co-cited articles
70 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Umberto Vitolo, Marek Trněný, David Belada, John M Burke, Angelo Michele Carella, Neil Chua, Pau Abrisqueta, Judit Demeter, Ian Flinn, Xiaonan Hong,[...]. J Clin Oncol 2017
243
58

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Ekkehard Mössner, Peter Brünker, Samuel Moser, Ursula Püntener, Carla Schmidt, Sylvia Herter, Roger Grau, Christian Gerdes, Adam Nopora, Erwin van Puijenbroek,[...]. Blood 2010
598
41

Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Valentin Goede, Kirsten Fischer, Raymonde Busch, Anja Engelke, Barbara Eichhorst, Clemens M Wendtner, Tatiana Chagorova, Javier de la Serna, Marie-Sarah Dilhuydy, Thomas Illmer,[...]. N Engl J Med 2014
41

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Bertrand Coiffier, Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard,[...]. N Engl J Med 2002
33

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Umberto Vitolo, Annalisa Chiappella, Silvia Franceschetti, Angelo Michele Carella, Ileana Baldi, Giorgio Inghirami, Michele Spina, Vincenzo Pavone, Marco Ladetto, Anna Marina Liberati,[...]. Lancet Oncol 2014
132
33

Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.
Franck Andre Morschhauser, Guillaume Cartron, Catherine Thieblemont, Philippe Solal-Céligny, Corinne Haioun, Reda Bouabdallah, Pierre Feugier, Krimo Bouabdallah, Elina Asikanius, Guiyuan Lei,[...]. J Clin Oncol 2013
156
33

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Robert Marcus, Andrew Davies, Kiyoshi Ando, Wolfram Klapper, Stephen Opat, Carolyn Owen, Elizabeth Phillips, Randeep Sangha, Rudolf Schlag, John F Seymour,[...]. N Engl J Med 2017
388
25

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Grzegorz S Nowakowski, Betsy LaPlant, William R Macon, Craig B Reeder, James M Foran, Garth D Nelson, Carrie A Thompson, Candido E Rivera, David J Inwards, Ivana N Micallef,[...]. J Clin Oncol 2015
276
25

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Kieron Dunleavy, Stefania Pittaluga, Myron S Czuczman, Sandeep S Dave, George Wright, Nicole Grant, Margaret Shovlin, Elaine S Jaffe, John E Janik, Louis M Staudt,[...]. Blood 2009
394
25

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
H Tilly, M Gomes da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, J Walewski, M André, P W Johnson, M Pfreundschuh,[...]. Ann Oncol 2015
434
25

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
Wyndham H Wilson, Sin-Ho Jung, Pierluigi Porcu, David Hurd, Jeffrey Johnson, S Eric Martin, Myron Czuczman, Raymond Lai, Jonathan Said, Amy Chadburn,[...]. Haematologica 2012
136
25

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Christian Récher, Bertrand Coiffier, Corinne Haioun, Thierry Jo Molina, Christophe Fermé, Olivier Casasnovas, Catherine Thiéblemont, André Bosly, Guy Laurent, Franck Morschhauser,[...]. Lancet 2011
247
25

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Richard Delarue, Hervé Tilly, Nicolas Mounier, Tony Petrella, Gilles Salles, Catherine Thieblemont, Serge Bologna, Hervé Ghesquières, Maya Hacini, Christophe Fruchart,[...]. Lancet Oncol 2013
203
25

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.
Sylvia Herter, Frank Herting, Olaf Mundigl, Inja Waldhauer, Tina Weinzierl, Tanja Fauti, Gunter Muth, Doris Ziegler-Landesberger, Erwin Van Puijenbroek, Sabine Lang,[...]. Mol Cancer Ther 2013
243
25

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
John Radford, Andrew Davies, Guillaume Cartron, Franck Morschhauser, Gilles Salles, Robert Marcus, Michael Wenger, Guiyuan Lei, Elisabeth Wassner-Fritsch, Umberto Vitolo. Blood 2013
97
25

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
25

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman,[...]. Lancet Oncol 2019
949
25

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
John P Leonard, Kathryn S Kolibaba, James A Reeves, Anil Tulpule, Ian W Flinn, Tatjana Kolevska, Robert Robles, Christopher R Flowers, Robert Collins, Nicholas J DiBella,[...]. J Clin Oncol 2017
103
16

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Gilles Salles, John Francis Seymour, Fritz Offner, Armando López-Guillermo, David Belada, Luc Xerri, Pierre Feugier, Réda Bouabdallah, John Vincent Catalano, Pauline Brice,[...]. Lancet 2011
750
16

Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.
Mathias Witzens-Harig, Axel Benner, Fabienne McClanahan, Jennifer Klemmer, Julia Brandt, Elke Brants, Michael Rieger, Julia Meissner, Manfred Hensel, Kai Neben,[...]. Br J Haematol 2015
25
16

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Catherine Thieblemont, Hervé Tilly, Maria Gomes da Silva, Rene-Olivier Casasnovas, Christophe Fruchart, Franck Morschhauser, Corinne Haioun, Julien Lazarovici, Anida Grosicka, Aurore Perrot,[...]. J Clin Oncol 2017
113
16

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Laurie H Sehn, Brian Berry, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry J Savage, Tamara Shenkier, Judy Sutherland,[...]. Blood 2007
928
16

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
David Cunningham, Eliza A Hawkes, Andrew Jack, Wendi Qian, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M Ardeshna, John A Radford, Andrew McMillan,[...]. Lancet 2013
342
16

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Thomas M Habermann, Edie A Weller, Vicki A Morrison, Randy D Gascoyne, Peter A Cassileth, Jeffrey B Cohn, Shaker R Dakhil, Bruce Woda, Richard I Fisher, Bruce A Peterson,[...]. J Clin Oncol 2006
16

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Bertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste, Gérard Lepeu, Isabelle Plantier, Sylvie Castaigne, Sophie Lefort, Gérald Marit, Margaret Macro, Catherine Sebban,[...]. Blood 2010
936
16

Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.
Kerry J Savage, Graham W Slack, Anja Mottok, Laurie H Sehn, Diego Villa, Roopesh Kansara, Robert Kridel, Christian Steidl, Daisuke Ennishi, King L Tan,[...]. Blood 2016
113
16


Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
Yasuhiro Oki, Mansoor Noorani, Pei Lin, Richard E Davis, Sattva S Neelapu, Long Ma, Mohamed Ahmed, Maria Alma Rodriguez, Fredrick B Hagemeister, Nathan Fowler,[...]. Br J Haematol 2014
248
16

Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.
Christina Howlett, Sonya J Snedecor, Daniel J Landsburg, Jakub Svoboda, Elise A Chong, Stephen J Schuster, Sunita Dwivedy Nasta, Tatyana Feldman, Allison Rago, Kristy M Walsh,[...]. Br J Haematol 2015
109
16



Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
Wyndham H Wilson, Kieron Dunleavy, Stefania Pittaluga, Upendra Hegde, Nicole Grant, Seth M Steinberg, Mark Raffeld, Martin Gutierrez, Bruce A Chabner, Louis Staudt,[...]. J Clin Oncol 2008
229
16

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, Devinder Singh Gill, David C Linch, Marek Trneny, Andre Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg,[...]. J Clin Oncol 2010
16

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Anas Younes, Catherine Thieblemont, Franck Morschhauser, Ian Flinn, Jonathan W Friedberg, Sandy Amorim, Benedicte Hivert, Jason Westin, Jessica Vermeulen, Nibedita Bandyopadhyay,[...]. Lancet Oncol 2014
209
16

Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Noelia Purroy, Juan Bergua, Laura Gallur, Julio Prieto, Luis A Lopez, Juan M Sancho, Jose A García-Marco, Josep Castellví, Santiago Montes-Moreno, Ana Batlle,[...]. Br J Haematol 2015
36
16

Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Thierry Jo Molina, Danielle Canioni, Christiane Copie-Bergman, Christian Recher, Josette Brière, Corinne Haioun, Françoise Berger, Christophe Fermé, Marie-Christine Copin, Olivier Casasnovas,[...]. J Clin Oncol 2014
62
16

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
16

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.
Laurie H Sehn, Sarit E Assouline, Douglas A Stewart, Joy Mangel, Randy D Gascoyne, Gregg Fine, Susan Frances-Lasserre, David J Carlile, Michael Crump. Blood 2012
118
16

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.
Gilles Salles, Franck Morschhauser, Thierry Lamy, Noel Milpied, Catherine Thieblemont, Hervé Tilly, Gabi Bieska, Elina Asikanius, David Carlile, Joe Birkett,[...]. Blood 2012
145
16


Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Laurie H Sehn, Neil Chua, Jiri Mayer, Gregg Dueck, Marek Trněný, Kamal Bouabdallah, Nathan Fowler, Vincent Delwail, Oliver Press, Gilles Salles,[...]. Lancet Oncol 2016
219
16

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
Laurie H Sehn, Andre Goy, Fritz C Offner, Giovanni Martinelli, M Dolores Caballero, Ole Gadeberg, Tara Baetz, Andrew D Zelenetz, Gianluca Gaidano, Luis E Fayad,[...]. J Clin Oncol 2015
125
16

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.
Gerhard Niederfellner, Alfred Lammens, Olaf Mundigl, Guy J Georges, Wolfgang Schaefer, Manfred Schwaiger, Andreas Franke, Kornelius Wiechmann, Stefan Jenewein, Jerry W Slootstra,[...]. Blood 2011
164
16

Lymphoma Immunotherapy: Current Status.
Roberta Zappasodi, Filippo de Braud, Massimo Di Nicola. Front Immunol 2015
33
16

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.
Christian Klein, Alfred Lammens, Wolfgang Schäfer, Guy Georges, Manfred Schwaiger, Ekkehard Mössner, Karl-Peter Hopfner, Pablo Umaña, Gerhard Niederfellner. MAbs 2013
197
16



Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
David W Scott, Anja Mottok, Daisuke Ennishi, George W Wright, Pedro Farinha, Susana Ben-Neriah, Robert Kridel, Garrett S Barry, Christoffer Hother, Pau Abrisqueta,[...]. J Clin Oncol 2015
239
16

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Anas Younes, Laurie H Sehn, Peter Johnson, Pier Luigi Zinzani, Xiaonan Hong, Jun Zhu, Caterina Patti, David Belada, Olga Samoilova, Cheolwon Suh,[...]. J Clin Oncol 2019
226
16

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Nancy L Bartlett, Wyndham H Wilson, Sin-Ho Jung, Eric D Hsi, Matthew J Maurer, Levi D Pederson, Mei-Yin C Polley, Brandelyn N Pitcher, Bruce D Cheson, Brad S Kahl,[...]. J Clin Oncol 2019
175
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.